title: Tetrazine-trans-cyclooctene ligation for the rapid construction of integrin αvβ₃ targeted PET tracer based on a cyclic RGD peptide.
abstract: Labeling biomolecules with (18)F is usually done through coupling with prosthetic groups, which generally requires several time-consuming radiosynthetic steps resulting in low labeling yield. Recently, the tetrazine-trans-cyclooctene ligation has been introduced as a method of bioconjugation that proceeds with fast reaction rates without need for catalysis. Herein, we report the development of an extremely fast and efficient method for generating (18)F labeled probes based on the tetrazine-trans-cyclooctene ligation. Starting with only 30 μg (78 μM) of a tetrazine-RGD conjugate and 2 mCi (5 μM) of (18)F-trans-cyclooctene, the (18)F labeled RGD peptide could be obtained in more than 90% yield within five minutes. The (18)F labeled RGD peptide demonstrated prominent tumor uptake in vivo. The receptor specificity was confirmed by blocking experiments. These results successfully demonstrate that the tetrazine-trans-cyclooctene ligation serves as an efficient labeling method for PET probe construction.
authors: Brown Laboratories, Department of Chemistry and Biochemistry, University of Delaware, Newark, DE 19803, USA.
authors: Ramajeyam
authors: R
authors: Selvaraj
authors: Shuanglong
authors: S
authors: Liu
authors: Matthew
authors: M
authors: Hassink
authors: Chiun-Wei
authors: CW
authors: Huang
authors: Li-Peng
authors: LP
authors: Yap
authors: Ryan
authors: R
authors: Park
authors: Joseph M
authors: JM
authors: Fox
authors: Zibo
authors: Z
authors: Li
authors: Peter S
authors: PS
authors: Conti
references: Science. 2003 Oct 24;302(5645):605-8
references: 14576425
references: Bioconjug Chem. 2008 Jun;19(6):1202-10
references: 18481886
references: J Fluor Chem. 2008 Sep;129(9):799-805
references: 19727427
references: Bioconjug Chem. 2007 Nov-Dec;18(6):1987-94
references: 18030991
references: J Am Chem Soc. 2004 Nov 24;126(46):15046-7
references: 15547999
references: Angew Chem Int Ed Engl. 2010 Apr 26;49(19):3375-8
references: 20391522
references: PLoS Med. 2005 Mar;2(3):e70
references: 15783258
references: J Pept Sci. 2009 Mar;15(3):235-41
references: 19177421
references: Mol Cancer Ther. 2003 Mar;2(3):335-43
references: 12657729
references: Bioconjug Chem. 2008 Dec;19(12):2297-9
references: 19053305
references: Chem Commun (Camb). 2010 Nov 14;46(42):8043-5
references: 20862423
references: J Am Chem Soc. 2008 Mar 26;130(12):3760-1
references: 18321114
references: Nat Rev Cancer. 2002 Sep;2(9):683-93
references: 12209157
references: Eur J Nucl Med Mol Imaging. 2007 Nov;34(11):1823-1831
references: 17492285
references: Bioconjug Chem. 2005 Mar-Apr;16(2):406-20
references: 15769096
references: J Nucl Med. 2007 Sep;48(9):1536-44
references: 17704249
references: Eur J Cancer. 2000 Oct;36(16):2028-35
references: 11044638
references: J Clin Invest. 2003 Jun;111(11):1620-9
references: 12782662
references: Nat Protoc. 2006;1(4):1655-61
references: 17487148
references: ChemMedChem. 2011 Mar 7;6(3):424-7
references: 21360818
references: Science. 1999 Aug 13;285(5430):1028-32
references: 10446041
references: Bioconjug Chem. 2003 Nov-Dec;14(6):1253-9
references: 14624642
references: Q J Nucl Med Mol Imaging. 2007 Jun;51(2):164-81
references: 17420717
references: Nucl Med Commun. 2000 Mar;21(3):234-6
references: 10823324
references: J Nucl Med. 2006 Jul;47(7):1172-80
references: 16818952
references: J Am Chem Soc. 2008 Oct 15;130(41):13518-9
references: 18798613
references: Cancer Res. 2001 Mar 1;61(5):1781-5
references: 11280722